Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,085,219 papers from all fields of science
Search
Sign In
Create Free Account
CDP870
Known as:
CDP870s
, 870s, CDP
, 870, CDP
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
certolizumab pegol
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
V. Ruíz García
,
A. Burls
,
J. Cabello
,
P. Vela Casasempere
,
S. Bort-Martí
,
J. Bernal
Cochrane Database of Systematic Reviews
2017
Corpus ID: 26299198
BACKGROUND Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) for…
Expand
Review
2010
Review
2010
TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion
Y. Wu
,
B. Zhou
British Journal of Cancer
2010
Corpus ID: 14944496
Tumour necrosis factor-alpha (TNF-α) is an important inflammatory factor that acts as a master switch in establishing an…
Expand
Review
2010
Review
2010
TNF-α and its inhibitors in cancer
I. Zidi
,
S. Mestiri
,
A. Bartegi
,
N. Amor
Medical Oncology
2010
Corpus ID: 23286761
Tumor necrosis factor (TNF)-α is implicated in the same time in apoptosis and in cell proliferation. TNF-α not only acts as pro…
Expand
Review
2009
Review
2009
Certolizumab pegol for the management of Crohn's disease in adults.
A. Rivkin
Clinical Therapeutics
2009
Corpus ID: 26469956
Highly Cited
2007
Highly Cited
2007
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor &agr; agents
A. Nesbitt
,
G. Fossati
,
+6 authors
T. Bourne
Inflammatory Bowel Diseases
2007
Corpus ID: 39555517
Background: Inhibitors of tumor necrosis factor &agr; (TNF&agr;) have demonstrated significant efficacy in chronic inflammatory…
Expand
Review
2006
Review
2006
Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
John T. Chang
,
G. Lichtenstein
Nature Clinical Practice Gastroenterology…
2006
Corpus ID: 29005347
In the past decade, advances in the understanding of the pathogenesis of inflammatory bowel disease have permitted the…
Expand
Highly Cited
2005
Highly Cited
2005
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
S. Schreiber
,
P. Rutgeerts
,
+7 authors
A. Innes
Gastroenterology
2005
Corpus ID: 32275891
BACKGROUND & AIMS To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti…
Expand
Highly Cited
2004
Highly Cited
2004
Pharmaceutical profiling in drug discovery for lead selection
R. Borchardt
2004
Corpus ID: 82410159
Absorption Prediction.- Predicting Molecular Physical Properties.- In Silico Transporter Modeling and Its Application in Drug…
Expand
Highly Cited
2004
Highly Cited
2004
Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study
T. Winter
,
J. Wright
,
S. Ghosh
,
J. Jahnsen
,
A. Innes
,
P. Round
Alimentary Pharmacology and Therapeutics
2004
Corpus ID: 42989422
Background : CDP870 is a PEGylated Fab′ fragment of a humanized monoclonal antibody that neutralizes tumour necrosis factor‐α.
Highly Cited
2002
Highly Cited
2002
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
E. Choy
,
B. Hazleman
,
+6 authors
D. Isenberg
Rheumatology
2002
Corpus ID: 27644928
OBJECTIVE Biological products that neutralize tumour necrosis factor alpha (TNF-alpha) are beneficial in rheumatoid arthritis (RA…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE